Truong San Phan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Truong San Phan has a total of 136 co-authors. Here are the top co-authors by number of shared publications:
- Ido Amit
Department of Systems Immunology, Weizmann Institute of Science, Rehovot, Israel
23 shared publications - Anna Gurevich-Shapiro
Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel
21 shared publications - Eyal David
Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel
21 shared publications - Pascale Zwicky
Department of Systems Immunology, Weizmann Institute of Science, Rehovot 7610001, Israel
21 shared publications - Mor Zada
Systems Immunology Department, Weizmann Institute of Science, Rehovot, Israel
19 shared publications - Abraham Avigdor
Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
18 shared publications
Latest Publications
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Table S11 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Performance metrics of predictive models
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S11 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Performance metrics of predictive models
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Table S10 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Features used to train the predictive models
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S10 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Features used to train the predictive models
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Immune composition at leukapheresis and infusion product in dependence of B-cell status
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Immune composition at leukapheresis and infusion product in dependence of B-cell status
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Detailed patients’ characteristics
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Detailed patients’ characteristics
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Clinical characteristics according to response status and B-cell phenotype
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Clinical characteristics according to response status and B-cell phenotype
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Table S4 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Pathways analysis in the T cell compartment of responders vs. non-responders
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Pathways analysis in the T cell compartment of responders vs. non-responders
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Top 30 differentially expressed genes in the T cell compartment
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Top 30 differentially expressed genes in the T cell compartment
- Open Access
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Gating strategy for scRNA-seq and characteristics of immune cell populations of DLBCL patients and healthy donors at the time of leukapheresis
- 18 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Distinct Cellular and Molecular Patterns in Pretreatment Peripheral Blood Are Associated with CAR T-cell Outcomes in Diffuse Large B-cell Lymphoma
Gating strategy for scRNA-seq and characteristics of immune cell populations of DLBCL patients and healthy donors at the time of leukapheresis